Article Data

  • Views 952
  • Dowloads 179

Original Research

Open Access Special Issue

Adjuvant radiotherapy of endometrial cancer: role of 18F-FDG-PET/CT in treatment modulation

  • Martina Ferioli1,2*,
  • Anna Myriam Perrone3,4
  • Paolo Castellucci5
  • Valeria Panni2
  • Anna Benini1,2
  • Gabriella Macchia6
  • Andrea Galuppi1
  • Milly Buwenge1,2
  • Elisa Lodi Rizzini1
  • Lidia Strigari7
  • Luca Tagliaferri8
  • Claudio Zamagni9
  • Pierandrea De Iaco3,4
  • Stefano Fanti5
  • Alessio Giuseppe Morganti1,2

1Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

2Radiation Oncology, Department of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, 40138 Bologna, Italy

3Oncologic Gynaecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

4Department Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy

5Nuclear Medicine Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

6Radiotherapy Unit, Gemelli Molise Hospital, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 86100 Campobasso, Italy

7Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

8UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, 00168 Rome, Italy

9Oncologia Medica Addarii, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy

DOI: 10.31083/j.ejgo4302028 Vol.43,Issue 2,April 2022 pp.219-226

Submitted: 31 October 2021 Accepted: 28 December 2021

Published: 15 April 2022

(This article belongs to the Special Issue Endometrial Cancer)

*Corresponding Author(s): Martina Ferioli E-mail: martina.ferioli4@unibo.it

Abstract

Objective: Residual disease after surgery is related to an unfavorable prognosis in patients with endometrial cancer (EC). An early diagnosis and treatment of this condition could improve patients’ outcome. Aim of this study was to define the role of postoperative 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (18F-FDG-PET/CT) in patients with high risk of residual disease after EC surgery. Methods: Patients operated for EC, with one or more risk factors, who underwent 18F-FDG-PET/CT before adjuvant treatment were included in this observational study. The primary endpoint was the rate of patients in whom 18F-FDG-PET/CT changed the treatment strategy and/or the radiotherapy (RT) planning. Results: Our analysis included 58 patients (median age: 67.5 years, range: 48.0–86.0) with the following risk factors: lymphadenectomy not performed (26 patients; 44.8%), inadequate lymphadenectomy (23 patients; 39.7%), and high risk of residual disease due to advanced stage (nine patients; 15.5%). Postoperative 18F-FDG-PET/CT imaging was positive in 18 patients (31%) in the following sites: pelvic extra-nodal disease (one patient), pelvic and/or paraaortic lymph nodes (12 patients), distant metastases (one patient), or combination of previous sites (four patients). Based on these results, the adjuvant therapeutic strategy was changed in five patients, three of whom were referred to chemotherapy alone due to distant metastases and two of whom were referred to nodal-directed treatment due to lymph node metastases (lymphadenectomy and pelvic chemoradiation plus boost, respectively). Furthermore, based on the 18F-FDG-PET/CT results, the RT plan was modified in 13 patients (addition of a boost on residual pelvic/abdominal disease in 12 and target modification in one, respectively). Therefore, based on postoperative 18F-FDG-PET/CT findings, the therapeutic strategy and the RT plan were changed in 5 patients (8.6%) and 13 patients (22.4%), respectively. Conclusion: In this analysis, the adjuvant treatment was modified after post-operative 18F-FDG-PET/CT in about one third of patients. Further studies are needed to better define the risk factors (or their combinations) correlated with higher probability of residual disease after radical hysterectomy-adnexectomy for EC.


Keywords

Endometrial cancer; Postoperative treatment; 18F-FDG-PET/CT; Radiotherapy; Concurrent chemoradiation; Brachytherapy

Cite and Share

Martina Ferioli,Anna Myriam Perrone,Paolo Castellucci,Valeria Panni,Anna Benini,Gabriella Macchia,Andrea Galuppi,Milly Buwenge,Elisa Lodi Rizzini,Lidia Strigari,Luca Tagliaferri,Claudio Zamagni,Pierandrea De Iaco,Stefano Fanti,Alessio Giuseppe Morganti. Adjuvant radiotherapy of endometrial cancer: role of 18F-FDG-PET/CT in treatment modulation. European Journal of Gynaecological Oncology. 2022. 43(2);219-226.

References

[1] McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer. 2016; 122: 2787–2798.

[2] Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018. Available at: https://gco.iarc.fr/today (Accessed: 18 March 2019).

[3] National Cancer Institute. SEER Stat Fact Sheets: Endometrial Cancer. 2020. Available at: https://seer.cancer.gov/statfacts/ht ml/corp.html (Accessed: 18 March 2020).

[4] Lewin SN, Herzog TJ, Medel NIB, Deutsch I, Burke WM, Sun X, et al. Comparative Performance of the 2009 International Federation of Gynecology and Obstetricsʼ Staging System for Uterine Corpus Cancer. Obstetrics & Gynecology. 2010; 116: 1141–1149.

[5] Lin MY, Dobrotwir A, McNally O, Abu‐Rustum NR, Narayan K. Role of imaging in the routine management of endometrial cancer. International Journal of Gynecology & Obstetrics. 2018; 143: 109–117.

[6] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27: 16–41.

[7] Erdemoğlu E, Çerçi SS, Erdemoğlu E, Yalçın Y, Tatar B. Role of positron emission tomography-computed tomography in endometrial cancer. Turkish Journal of Obstetrics and Gynecology. 2017; 14: 203–209.

[8] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Uterine Neoplasms Version 1.2020. 2019. Available at: https://www.nccn.org/profe ssionals/physician_gls/pdf/uterine.pdf (Accessed: 3 July 2020).

[9] Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24: vi33–vi38.

[10] Grégoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report no. 83). Cancer/RadiothéRapie. 2011; 15: 555–559.

[11] Small W, Beriwal S, Demanes DJ, Dusenbery KE, Eifel P, Erickson B, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012; 11: 58–67.

[12] Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet. 2019; 393: 2051–2058.

[13] Simcock B, Narayan K, Drummond E, Bernshaw D, Wells E, Hicks RJ. The Role of Positron Emission Tomogra-phy/Computed Tomography in Planning Radiotherapy in Endometrial Cancer. International Journal of Gynecologic Cancer. 2015; 25: 645–649.

[14] Ozcan Kara P, Kara T, Kaya B, Gedik GK, Sari O. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Revista EspañOla De Medicina Nuclear E Imagen Molecular. 2012; 31: 257–260.

[15] Sharma P, Kumar R, Singh H, Jeph S, Sharma DN, Bal C, et al. Carcinoma Endometrium. Clinical Nuclear Medicine. 2012; 37: 649–655.

[16] Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: Systematic review and meta-analysis of the literature. Gynecologic Oncology. 2013; 128: 397–404.

[17] Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, Salvesen HB, Haldorsen IS. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. Journal of Nuclear Medicine. 2016; 57: 879–885.

[18] Crivellaro C, Signorelli M, Guerra L, De Ponti E, Pirovano C, Fruscio R, et al. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecologic Oncology. 2013; 130: 306–311.

[19] Antonsen SL, Jensen LN, Loft A, Berthelsen AK, Costa J, Tabor A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer — a multicenter prospective comparative study. Gynecologic Oncology. 2013; 128: 300–308.

[20] Kitajima K, Suzuki K, Senda M, Kita M, Nakamoto Y, Sakamoto S, et al. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? Annals of Nuclear Medicine. 2011; 25: 511–519.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top